Page 181 - Genentech News Today

VANCOUVER, British Columbia — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today…

Some who spent considerable time and resources to enter the $1 million contest launched by state education officials say it was a sham, drumming up attention but demanding a miracle and turning down practical ideas.

Clinical data found “no evidence” of a higher short-term cancer risk, except for non-melanoma skin cancer, in patients with rheumatoid arthritis or psoriatic arthritis starting Janus kinase inhibitors vs. TNF inhibitors, researchers wrote.

Organized by the CSU Student Chapter of the American Society of Landscape Architects, the 30th annual LA Days program features five speakers at the cutting edge of the profession and represents the broad spectrum of scale and scope that constitutes contemporary practice in landscape architecture.

Oliver Dorigo, MD, PhD, explains how MVP-S leverages the DPX platform to produce persistent anti-survivin immune infiltration, highlights the antitumor activity and safety observed with the combination when given to patients with recurrent ovarian cancer, and describes additional research efforts underway.

“It wasted precious resources and time": $1 million California education contest to close student digital divide ends in a bust

The biotechnology firm revealed new allegations of research misconduct in Marc Tessier-Lavigne’s lab and disclosed more potential image alterations while saying that its potentially “incomplete” findings did not prove fraud in a contested 2009 study.

Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.

Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.

Research at Biogen